CalciMedica Reports Topline Data from the AuxoraTM CARDEA Phase 2 COVID-19 Pneumonia Clinical Trial

Link to full article Reduction in time to recovery through day 60 in patients with moderate and severe respiratory failure (primary endpoint analysis) Statistically significant reduction in time to recovery through day 60 in all patients who received study drug (a pre-specified supplementary analysis of the primary endpoint) Statistically significant 56% relative risk reduction in […]

CalciMedica Announces Publication of Preclinical Data in Journal of Immunology Further Validating Calcium Release-Activated Calcium (CRAC) Channels as Drug Targets for Diseases of the Airways

Link to full article Data provides further evidence of the broad potential for CRAC channel inhibitors to benefit patients across multiple disease areas involving the lungs LA JOLLA, Calif., September 9, 2021 – CalciMedica Inc. (“CalciMedica” or the “Company”), the CRAC channel company, today announced the publication of preclinical data validating calcium release-activated calcium (CRAC) channels, P2Y2 […]

Spray-on skin technology saving lives of many in Australia and around the world

The Bali bombing in 2002 caused the shocking deaths of 202 people, including 88 Australians. A further 209 were injured, many with disfiguring burns. But thanks to plastic surgeon Professor Fiona Wood, from the Royal Perth Hospital, a spray-on skin she invented saved many lives. RECELL continues to do so today around the world, thanks […]

Armata Pharmaceuticals Announces Second Quarter Results and Provides General Corporate Update

Link to Full Article Continues to advance AP-PA02 through Phase 1b/2a clinical trial as a potential treatment for cystic fibrosis patients with chronic Pseudomonas aeruginosa Announced that Todd R. Patrick, CEO, has retired from the Company. Brian Varnum, PhD, former President and Chief Development Officer, has been appointed the Company’s new CEO MARINA DEL REY, […]

Destiny Pharma

Acrux receives FDA approval for its generic version of EMLA® (Lidocaine 2.5% and Prilocaine 2.5%) Cream

Melbourne, Australia; 28 July 2021: Acrux Limited (ASX:ACR) (‘Acrux’ or the ‘Company’) is pleased to announce that the US Food and Drug Administration (‘FDA’) has approved its generic version of EMLA® (Lidocaine 2.5% and Prilocaine 2.5%) Cream. In June 2019, Acrux submitted an ANDA to seek approval from the FDA to market its generic version […]


Link to Full Article GENinCode Plc are pleased to announce the publication of its Thrombo inCode® prospective case-control study performed at the Karolinska Institute, Sweden. The positive clinical results strengthen Thrombo inCode® as a leading diagnostic for the diagnosis of inherited thrombophilia and venous thromboembolism (“VTE”). The study returned positive clinical results which strengthen Thrombo […]


Link to Full Article GENinCode the predictive genetics and cardiovascular disease company focused on the prevention of cardiovascular disease is thrilled to announce the completion of its IPO and subsequent listing on the London Stock Exchange. NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE REPUBLIC OF IRELAND OR […]

Congenica Receives CE Mark for Genomic Analysis Software

Link to Full Article Cambridge, United Kingdom – Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform people’s lives, today announces that its genomic interpretation software is now CE marked under the In Vitro Diagnostics Directive (98/79/EC). With the In Vitro Diagnostic (IVD) designation, Congenica’s clinical decision support platform […]